Randy Schrecengost
Principal investigator, leads TARGEPEUTICS, INC..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$330KFederal grants as PI2 awards
0Patents grantedNone matched
76Papers1,946 citations
Federal awards and patents by year
AwardsPatents
2 awards · $330K
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 5, 2023 | NIH | SBIR Phase I Development of GB13 for the Treatment of Pediatric Diffuse Intrinsic Pontine Glioma | $55K | TARGEPEUTICS, INC. |
| Aug 31, 2022 | NIH | SBIR Phase I Development of GB13 for the Treatment of Pediatric Diffuse Intrinsic Pontine Glioma | $275K | TARGEPEUTICS, INC. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#2,813
Awards as PI#1,252
Patents#273
Companies
- TARGEPEUTICS, INC.Leads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.